Floatz logo

Bortezomib

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.

Asset / SponsorPhaseRating
Carboplatin
Cardiff University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BBB
VINBLASTINE
University of Southern California
Phase 3BBB
Inno-206
University of Southern California
Phase 3BBB
FILGRASTIM
Tulane University Health Sciences Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →